The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-859 after single ascending doses in healthy adult volunteers.
Inclusion Criteria:
Exclusion Criteria:
abbvieclinicaltrials@abbvie.com844-663-3742
Participants will receive either ABBV-859 single Dose A, or the Placebo equivalent, on Study Day 1
Participants will receive either ABBV-859 single Dose B, or the Placebo equivalent, on Study Day 1
Participants will receive either ABBV-859 single Dose C, or the Placebo equivalent, on Study Day 1
Participants will receive either ABBV-859 single Dose D, or the Placebo equivalent, on Study Day 1
Participants will receive either ABBV-859 single Dose E, or the Placebo equivalent, on Study Day 1
Participants will receive either ABBV-859 single Dose F, or the Placebo equivalent, on Study Day 1
Participants will receive either ABBV-859 single Dose G, or the Placebo equivalent, on Study Day 1
Participants will receive either ABBV-859 single Dose H, or the Placebo equivalent, on Study Day 1
A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants
A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants
A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants
A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants